Roles of FGF20 in dopaminergic neurons and Parkinson's disease

Frontiers in Molecular Neuroscience

Volumn , Issue MAY, 2013, Pages

  Itoh, Nobuyuki ^a   Ohta, Hiroya ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Dopaminergic neurons; FGF; FGF20; Parkinson's disease; Snp; Stem cells

Indexed keywords

ALPHA SYNUCLEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 20; NUCLEAR RECEPTOR RELATED FACTOR 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BRAIN REGION; CELL DEATH; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; EMBRYONIC STEM CELL; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NONHUMAN; PARACRINE SIGNALING; PARKINSON DISEASE; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84878318898     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2013.00015     Document Type: Article

References (25)

1. Clarimon, J., Xiromerisiou, G., Eerola, J., Gourbali, V., Hellström, O., Dardiotis, E., Peuralinna, T., Papadimitriou, A., Hadjigeorgiou, G.M., Tienari, P.J., and Singleton AB. (2005). Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients. BMC Neurol. 5, 11.
2. Correia, A.S., Anisimov, S.V., Roybon, L., Li, J.Y., and Brundin, P. (2007). Fibroblast growth factor-20 increases the yield of midbrain dopaminergic neurons derived from human embryonic stem cells. Front. Neuroanat. 1, 4.
3. de Mena, L., Cardo, L.F., Coto, E., Miar, A., Díaz, M., Corao, A.I., Alonso, B., Ribacoba, R., Salvador, C., Menéndez, M., Morís, G., and Alvarez, V. (2010). FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson's disease in Spanish patients. Neurosci. Lett. 479, 22-5.
4. Gao, X., Scott, W.K., Wang, G., Mayhew, G., Li, Y.J., Vance, J.M., and Martin, E.R. (2008). Gene-gene interaction between FGF20 and MAOB in Parkinson disease. Ann. Hum. Genet. 72, 157-162.
5. Gibson, S.A., Gao, G.D., McDonagh, K., and Shen, S. (2012). Progress on stem cell research towards the treatment of Parkinson's disease. Stem Cell Res. Ther. 3, 11.
6. Grothe, C., Timmer, M., Scholz, T., Winkler, C., Nikkhah, G., Claus, P., Itoh, N., and Arenas, E. (2004). Fibroblast growth factor-20 promotes the differentiation of Nurr1-overexpressing neural stem cells into tyrosine hydroxylase-positive neurons. Neurobiol. 17, 163-170.
7. International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2). (2011). A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet.7, e1002142.
8. Itoh, N, and Ornitz, D.M. (2011). Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 149, 121-130.
9. Murase, S., and McKay, R.D. (2006). A specific survival response in dopamine neurons at most risk in Parkinson's disease. J. Neurosci. 26, 9750-9760.
10. Mizuta, I., Tsunoda, T., Satake, W., Nakabayashi, Y., Watanabe, M., Takeda, A., Hasegawa, K., Nakashima, K., Yamamoto, M., Hattori, N., Murata, M., and Toda, T. (2008). Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. Hum. Genet.124, 89-94.
11. Ohmachi, S., Watanabe, Y., Mikami, T., Kusu, N., Ibi, T., Akaike, A., and Itoh, N. (2000). FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem. Biophys. Res. Commun. 277, 355-360.
12. Ohmachi, S., Mikami, T., Konishi, M., Miyake, A., and Itoh, N. (2003). Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c. J. Neurosci. Res. 72, 436-443.
13. Pan, J., Li, H., Wang, Y., Ma, J.F., Zhang, J., Wang, G., Liu, J., Wang, X.J., Xiao, Q., and Chen, S.D. (2012). Fibroblast growth factor 20 (FGF20) polymorphism is a risk factor for Parkinson's disease in Chinese population. Parkinsonism Relat. Disord. 18, 629-631.
14. Pihlstrøm, L., Axelsson, G., Bjørnarå, K.A., Dizdar, N., Fardell, C., Forsgren, L., Holmberg, B., Larsen, J.P., Linder, J., Nissbrandt, H., Tysnes, O.B., Ohman, E., Dietrichs, E., and Toft, M. (2013). Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease. Neurobiol. Aging 34, 1708.e7-e13.
15. Sanchez-Pernaute, R., Lee, H., Patterson, M., Reske-Nielsen, C., Yoshizaki, T., Sonntag, K.C., Studer, L., and Isacson, O. (2008). Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease. Brain 131, 2127-2139.
16. Satake, W., Mizuta, I., Suzuki, S., Nakabayashi, Y., Ito, C., Watanabe, M., Takeda, A., Hasegawa, K., Sakoda, S., Yamamoto, M., Hattori, N., Murata, M., and Toda, T. (2007). Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population. Neuroreport, 18, 937-940.
17. Shimada, H., Yoshimura, N., Tsuji, A., and Kunisada, T. (2009). Differentiation of dopaminergic neurons from human embryonic stem cells: modulation of differentiation by FGF-20. J. Biosci. Bioeng. 107, 447-454.
18. Sleeman, I.J., Boshoff, E.L., and Duty, S. (2012). Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neuropharmacology. 63, 1268-1277.
19. Takagi, Y., Takahashi, J., Saiki, H., Morizane, A., Hayashi, T., Kishi, Y., Fukuda, H., Okamoto, Y., Koyanagi, M., Ideguchi, M., Hayashi, H., Imazato, T., Kawasaki, H., Suemori, H., Omachi, S., Iida, H., Itoh, N., Nakatsuji, N., Sasai, Y., and Hashimoto, N. (2005). Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J. Clin. Invest. 115, 102-109.
20. Thisse, B., and Thisse, C. (2005). Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev. Biol. 287, 390-402.
21. van der Walt, J.M., Noureddine, M.A., Kittappa, R., Hauser, M.A., Scott, W.K., McKay, R., Zhang, F., Stajich, J.M., Fujiwara, K., Scott, B.L., Pericak-Vance, M.A., Vance, J.M., and Martin, E.R. (2004). Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am. J. Hum. Genet. 74,1121-1127.
22. Wang, G., van der Walt, J.M., Mayhew, G., Li, Y.J., Züchner, S., Scott, W.K., Martin, E.R., and Vance, J.M. (2008). Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am. J. Hum. Genet. 82, 283-289.
23. Wang, M., Wang, L., Jiang, N., Jia, T., and Luo, Z. (2013). A robust and efficient statistical method for genetic association studies using case and control samples from multiple cohorts. BMC Genomics, 14, 88.
24. Wider, C., Dachsel, J.C., Soto, A.I., Heckman, M.G., Diehl, N.N., Yue, M., Lincoln, S., Aasly, J.O., Haugarvoll, K., Trojanowski, J.Q., Papapetropoulos, S., Mash, D., Rajput, A., Rajput, A.H., Gibson, J.M., Lynch, T., Dickson, D.W., Uitti, R.J., Wszolek, Z.K., Farrer, M.J., and Ross, O.A. (2009). FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. Mov. Disord. 24, 455-459.
25. Zhang, X., Ibrahimi, O.A., Olsen, S.K., Umemori, H., Mohammadi, M., and Ornitz, D.M. (2006). Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281, 15694-15700.